NasdaqGM:PRCTMedical Equipment
A Look At PROCEPT BioRobotics (PRCT) Valuation After New European Aquablation Guideline Upgrade
Why the new European guidelines matter for PROCEPT BioRobotics (PRCT)
The European Association of Urology has upgraded Aquablation therapy to a strong recommendation for benign prostatic hyperplasia, a shift backed by multiple clinical trials and expanding international guideline support.
See our latest analysis for PROCEPT BioRobotics.
Despite the strong guideline upgrade, PROCEPT BioRobotics' 90 day share price return of 18.34% and 1 year total shareholder return of 50.97% indicate pressure...